Abstract
Immune checkpoint inhibitors have failed in treating mCRC patients (pts) except those with MSI/dMMR tumours. However, in pts with MSI/dMMR mCRC, only one randomized trial in the first-line setting, showed the superiority of an anti-programmed death 1 (anti–PD-1) antibody over standard treatment. The SAMCO-PRODIGE 54 trial aimed to evaluate efficacy and safety of an anti-programmed death ligand-1 (anti–PD-L1) antibody compared with a standard treatment in the second-line setting in pts with MSI/dMMR mCRC.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
